The dual opt-in options make for an unusual deal structure, but they give MNTA the financial flexibility it sought in light of the unknown near-term revenue stream from 40mg Copaxone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”